Results 41 to 50 of about 52,625 (269)

Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer

, 2022
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast ...
Andrea Walens (15849066), Melissa A. Troester (15051839), Erin L. Kirk (15849075), Cyrus Vaziri (15849078), Xiaohua Gao (15136527), Sarah C. Van Alsten (15136524), Charles M. Perou (11303973), Michael I. Love (15130904), Katherine A. Hoadley (15010872), Linnea T. Olsson (15109165), Alina M. Hamilton (15136521), Markia A. Smith (15849069), Gaorav P. Gupta (15134144), Alex Lockhart (15849072)   +13 more
core   +3 more sources

Genomic Signature of Homologous Recombination Deficiency in Breast and Ovarian Cancers

Bio-Protocol, 2013
Homologous recombination deficiency, mainly resulted from BRCA1 or BRCA2 inactivation (so called BRCAness), is found in breast and ovarian cancers. Detection of actual inactivation of BRCA1/2 in a tumor is important for patients’ treatment and follow-up ...
Popova Tatiana, Elodie Manié, Marc-Henri Stern   +2 more
doaj   +1 more source

Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery

Frontiers in Molecular Biosciences, 2022
Identifying BRCA mutations and homologous recombination deficiency (HRD) is the key to choosing patients for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
Huan Yi, Linhong Li, Jimiao Huang, Zhiming Ma, Hongping Li, Jian Chen, Xiangqin Zheng, Jingjing Chen, Haixin He, Jianrong Song   +9 more
doaj   +1 more source

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers

Nature Communications, 2020
BRCA-deficient breast cancer is characterised by homologous recombination deficiency. Here, the authors show that hypermethylated BRCA1 phenotypically copies mutated BRCA1 in triple negative breast cancers.
Dominik Glodzik, Ana Bosch, Johan Hartman, Mattias Aine, Johan Vallon-Christersson, Christel Reuterswärd, Anna Karlsson, Shamik Mitra, Emma Niméus, Karolina Holm, Jari Häkkinen, Cecilia Hegardt, Lao H. Saal, Christer Larsson, Martin Malmberg, Lisa Rydén, Anna Ehinger, Niklas Loman, Anders Kvist, Hans Ehrencrona, Serena Nik-Zainal, Åke Borg, Johan Staaf   +22 more
doaj   +1 more source

PARP inhibitors for homologous recombination-deficient prostate cancer [PDF]

Expert Opinion on Emerging Drugs, 2018
Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant disease.
Eric S, Christenson, Emmanuel S, Antonarakis   +1 more
openaire   +2 more sources

Prediction of homologous recombination deficiency from cancer gene expression data

Journal of International Medical Research, 2022
Objective Homologous recombination deficiency (HRD) is the main mechanism of tumorigenesis in some cancers. HRD causes abnormal double-strand break repair, resulting in genomic scars.
Jun Kang, Jieun Lee, Ahwon Lee, Youn Soo Lee   +3 more
doaj   +1 more source

Distinct roles for two RAD51-related genes in Trypanosoma brucei antigenic variation

, 2005
In Trypanosoma brucei, DNA recombination is crucial in antigenic variation, a strategy for evading the mammalian host immune system found in a wide variety of pathogens.
Proudfoot, C, McCulloch, Richard, Proudfoot, Christopher, McCulloch, R   +3 more
core   +1 more source

Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities

Nature Communications, 2022
The molecular landscape of breast cancer brain metastases (BCBM) is still understudied, especially for different breast cancer subtypes. Here, the authors characterise subtype-specific BCBMs using genomics and transcriptomics and identify homologous ...
Nicola Cosgrove, Damir Varešlija, Stephen Keelan, Ashuvinee Elangovan, Jennifer M. Atkinson, Sinéad Cocchiglia, Fiona T. Bane, Vikrant Singh, Simon Furney, Chunling Hu, Jodi M. Carter, Steven N. Hart, Siddhartha Yadav, Matthew P. Goetz, Arnold D. K. Hill, Steffi Oesterreich, Adrian V. Lee, Fergus J. Couch, Leonie S. Young   +18 more
doaj   +1 more source

Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer

, 2023
Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer, Amy Bodrog, MD, Lipson Cancer Institute Objectives: Discuss how PARP inhibitors work.
Bodrog, Amy
core  

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications

, 2021
Tumors with homologous recombination (HR) deficiency (HRD) show high sensitivity to platinum salts and PARP-inhibitors in several malignancies.
Spetzler, David, Elliott, Andrew, Cremolini, Chiara, Zhang, Jian, Tamburini, Emiliano, Antoniotti, Carlotta, Lopes, Gilberto, Xiu, Joanne, Santini, Daniele, Lonardi, Sara, Tomasello, Gianluca, Lenz, Heinz-Josef, Arai, Hiroyuki, Passardi, Alessandro, Shields, Anthony, Korn, Michael, Rossini, Daniele, Aprile, Giuseppe, Marshall, John, Masi, Gianluca, Germani, Marco Maria, Conca, Veronica, Moretto, Roberto, Abraham, Jim, Pietrantonio, Filippo, Falcone, Alfredo, Oberley, Matthew, Stafford, Phillip   +27 more
core   +1 more source